Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Breast Cancer 2024

Post neoadjuvant systemic treatment decisions

HR-positive/HER2-negative: When to use CDK4/6 inhibitors, including gBRCA1/2mut patients?

Date

15 May 2024

Session

Post neoadjuvant systemic treatment decisions

Topics

Tumour Site

Breast Cancer

Presenters

Carmen Criscitiello

Authors

C. Criscitiello

Author affiliations

  • IEO - Istituto Europeo di Oncologia IRCCS, Milan/IT

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A and discussion

Session: Post neoadjuvant systemic treatment decisions

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.